The inflammatory bowel diseases, of unknown etiology and for which there are no cures, continue to attract the attention and interest of gastroenterologists, internists and surgeons. International symposia are common and it is safe to say that there is at least one major symposium held somewhere in the world each year. This book encompasses the proceedings of two recent symposia held in Victoria, British Columbia, Canada. The symposia were the fifth and sixth international meetings focused on inflammatory bowel disease in Canada in the last eight years. Once again they were sponsored by Axcan Pharma, Inc. (formerly Interfalk Canada, Inc.) and endorsed by the Canadian Association of Gastroenterology. As has become traditional at such meetings the faculty was drawn from an international roster ofleaders in the field of inflammatory bowel disease and gastroenterology. The chapters of the proceedings provide a timely, up-to-date review of the major issues, including those within the realm of basic science and others dealing with clinical problems. The first symposium, 'Basic Research and Clinical Implications', was co-ordinated by John Wallace in association with Stephen Collins and Stephan Targan. The themes of this section were organized under the general topics of predisposing factors (genetics, animal models, infection, permeability, and immune deficits) and the pathophysiology of intestinal inflammation. The second symposium, Trends in Therapy' was organized by Lloyd Sutherland along with Franc;:ois Martin, Robin McLeod and Noel Williams.

Inhaltsangabe1: Basic Research and Clinical Implications in IBD.- Section I: Predisposing Factors in the Etiology of IBD: What We Can Learn from Animal Models.- 1 Subclinical markers of human IBD.- 2 Genetic factors in animal models of intestinal inflammation.- 3 Multifactorial control of autoimmune insulin-dependent diabetes in NOD mice: lessons for inflammatory bowel disease.- 4 Genetics of complex diseases: from mouse to man and back.- Section II: Predisposing Factors in the Etiology of IBD: Bugs, Drugs and Leaks.- 5 Crohn's disease: the pathogenesis of a granulomatous vasculitis: a hypothesis.- 6 Intestinal permeability: the basics.- Section III: Predisposing Factors in the Etiology of IBD: Is There a Primary Immune Defect?.- 7 Etiology of organ-specific autoimmunity.- 8 Regulation of mucosal immune responses - the missing link in IBD?.- 9 T cell repertoire and IBD.- 10 On the pathogenesis trail: what marker B cell clones tell us about IBD.- Section IV: Pathophysiology of Intestinal Inflammation: Intracellular and Intercellular Signalling.- 11 Growth factors in IBD.- 12 Nitric oxide and chronic colitis.- Section V: Pathophysiology of Intestinal Inflammation: Symptom Generation In IBD.- 13 Cytokine interactions with epithelium.- 14 Immunomodulation of epithelium.- 15 The enteric nervous system in intestinal inflammation.- 16 The role of smooth muscle in intestinal inflammation.- 17 Brain-gut interactions in IBD: mechanisms of anorexia in animal models of experimental colitis.- 2: Trends in IBD Therapy 1994.- Section VI: Critical Appraisal of Clinical Trials.- 18 How to critically appraise a clinical trial.- 19 Finding the right index for IBD.- 20 Special problems associated with surgical trials in IBD.- 21 Trends in IBD therapy: a meta-analytic approach.- Section VII: Basic Science: Genetics, Markers and Models.- 22 New IBD markers: definition of disease heterogeneity.- 23 Lessons in IBD pathogenesis from new animal models of spontaneous colitis.- 24 Potential human models of IBD.- Section VIII: Basic Science: Pathogenesis.- 25 New concepts of pathogenesis in IBD.- 26 The gut-brain axis in IBD: an investigator's perspective.- 27 Gut-brain interactions in IBD: a clinician's perspective.- Section IX: Surgical Issues in IBD.- 28 Cancer risk in IBD.- 29 Management of stomal complications.- 30 Indications and contraindications to reconstructive surgery in ulcerative colitis.- 31 Pouchitis - what's new in etiology and management?.- 32 Laparoscopic techniques: what is the role in IBD?.- Section X: Lifestyle in IBD.- 33 Smoking.- 34 Nutritional advice.- 35 IBD, the oral contraceptive pill and pregnancy.- 36 The social toll of IBD.- 37 Insurance rating of patients with IBD: a report of a conference on morbidity and mortality.- Section XI: Therapeutics.- 38 Overview of 5-ASA in the therapy of IBD.- 39 Immunosuppressive agents in IBD: current status and future prospects.- 40 Novel targets for anti-inflammatory therapy in IBD.- Section XII: Therapy in IBD in 1994.- 41 A gastroenterologist's perspective of the medical management of patients with Crohn's disease and ulcerative colitis.- 42 Therapy of IBD in 1994: a surgeon's perspective.